Correction: Ceftolozane-tazobactam in nosocomial pneumonia
- PMID: 36173368
- PMCID: PMC9548067
- DOI: 10.37201/req/erratum01.2022
Correction: Ceftolozane-tazobactam in nosocomial pneumonia
Abstract
This corrects the article DOI: 10.37201/req/s01.08.2022.
Erratum for
-
Ceftolozane-tazobactam in nosocomial pneumonia.Rev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):35-39. doi: 10.37201/req/s01.08.2022. Epub 2022 Apr 22. Rev Esp Quimioter. 2022. PMID: 35488823 Free PMC article. Review.
Similar articles
-
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.J Clin Pharmacol. 2021 Feb;61(2):254-268. doi: 10.1002/jcph.1733. Epub 2020 Sep 18. J Clin Pharmacol. 2021. PMID: 32949031 Free PMC article. Clinical Trial.
-
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.J Clin Pharmacol. 2016 Jan;56(1):56-66. doi: 10.1002/jcph.566. Epub 2015 Aug 25. J Clin Pharmacol. 2016. PMID: 26096377 Free PMC article. Clinical Trial.
-
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.Crit Care. 2021 Aug 11;25(1):290. doi: 10.1186/s13054-021-03694-3. Crit Care. 2021. PMID: 34380538 Free PMC article. Clinical Trial.
-
An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia.Expert Opin Pharmacother. 2020 Jun;21(9):1005-1013. doi: 10.1080/14656566.2020.1739269. Epub 2020 Mar 26. Expert Opin Pharmacother. 2020. PMID: 32212866 Review.
-
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.Ther Clin Risk Manag. 2016 May 19;12:787-97. doi: 10.2147/TCRM.S83844. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27279744 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources